DEVELOPMENT

发展基金 本申请要求每年共计50万美元的发展资金，用于：1)试点项目；2) 新的调查人员/招聘，以及3)开发共享资源。 发展基金是该中心成长和发展的财务基础。CCSG 与其他机构来源相结合，为新科学家、新资源创造一个总投资池 和科学。在过去的赠款期间，总共投资了4596,819美元用于试点项目，新的 调查人员和共享资源。其中1,417,500美元来自CCSG发展基金，以及 3,179,319美元由其他癌症中心基金提供。目前的投资回报为10,953,939美元；a 138%的投资回报率。在CCSG的1,417,500美元资金中，有668.000美元投资于试点项目。校外补助金 这些试点项目的收益为5 069 686美元，回报为6倍。获得的校外赠款 这些受援者虽然不一定是试点项目数据的直接结果，但数额达25 641 499美元。 协管组用于征聘/新调查员的资金为672.500美元(外加2,302,349美元的其他基金)。 CCSG的投资回报为7,134,253美元，ROI为961%。在描述未来投资的同时， 并应与中心的总体战略规划联系起来看待，同样重要的是系统 被用来确定需求和关于资金分配的决策程序。 招聘和新调查员的追求通常遵循结构化分析，其中包括：1)来自 计划和高级领导人；2)确定优先级别和可用的财政资源。例如, 2004年的战略计划得出结论，需要更多的临床科学家；这两个人都被禁足了 在临床研究以及实验室和临床共同关注的领域。该计划注意到打算进一步 扩大癌症中心，并将其与包括信息学和工程学在内的物理科学联系起来。 随后与计划和高级领导进行了讨论，然后与学术界进行了讨论和谈判 部门主席，以确定部门职位和可用于此类工作的资源 预约。紧随其后的是成立一个搜索委员会。这就是我们所遵循的道路 招聘Tony Reid，MD，PhD，Gregory Daniels，MD，Phd和Catriona Jamieson，MD，PhD，The 加入摩尔癌症中心的有前途的新的翻译研究科学家。 试点项目被用来实施该中心计划的其他部分；即，指导我们较年轻的 临床科学家和开发具有临床终点的转化性研究项目。这些目标来自于 最近实施的两个试点项目竞赛-指导翻译研究奖-赋予生活 计划和协作翻译研究奖计划，详细描述如下。这些节目 每年每隔六个月向癌症中心成员宣布一次，竞争激烈， NIH多层次评审方式的评选。来自CCSG的试点项目资金也与其他 癌症中心的资金。 中心和生物工程系之间的联合征聘，包括分配一个 FTE，正在为一位有成就的癌症生物工程学家进行。通过利用校园创业 资助和3个指定FTE，Nicholas Schork博士，加州大学圣地亚哥分校精神病学教授，专门研究 生物信息学博士于2005年被聘为我们生物信息学项目的新调查员和负责人。不是 他的招聘需要CCSG的资金，尽管CCSG可能会分配给 这个关键区域。 正在通过新的科学方向、需求评估来开发技术和共享资源 通过定期成员调查和领导层确定最佳支持服务。在这段历史中 在项目期间，我们投资了旨在改进基因组数据分析的技术。未来 癌症中心成员和领导都对服务给予了认真考虑，并提出了 协调委员会对三个发展中设施的拨款密切反映了中心的方案优先事项。 下面将对这些内容进行详细描述

DEVELOPMENTAL FUNDS A total of $500,000 per year in Developmental Funds is requested in this application for: 1) Pilot Projects; 2) New Investigators / Recruitment, and 3) Developing Shared Resources. Developmental Funds represent the financial foundation of growth and development of the Center. The CCSG is leveraged with other institutional sources to create a total investment pool toward new scientists, resources and science. During the past grant period, a total of $4,596,819 were invested in pilot projects, new investigators and shared resources. Of this amount, $1,417,500 came from CCSG Developmental Funds, and $3,179,319 was provided from other Cancer Center funds. The current return on investment is $10,953,939; a 138% ROI. Of the $1,417,500 in CCSG funds, $668.000 was invested in pilot projects. Extramural grants obtained as a result of those pilot projects amount to $5,069,686; a 6-fold return. Extramural grants obtained by those recipients, although not necessarily directly resulting from pilot project data, amount to $25,641,499. CCSG funds invested in Recruitment/New Investigators amount to $672.500 (plus $2,302,349 in other funds). That CCSG investment has returned $7,134,253, an ROI of 961%. While the future investments are described, and should be viewed in relation to the overall strategic plans of the Center, equally important are the systems employed to identify needs and the decision-making process that is in place regarding funding allocations. Recruitment and new investigator pursuits generally follows a structured analysis that includes: 1) input from program and senior leaders and; 2) identifying the priority level and available financial resources. For example, the 2004 Strategic Plan concludes that a greater number of clinical scientists are needed; those both grounded in clinical research and those with joint laboratory and clinical interests. The Plan notes the intention to further expand and link the Cancer Center with the physical sciences, including informatics and engineering. Discussions followed with program and senior leadership, then to discussion and negotiation with academic department chairs in order to determine the departmental positions and resources available for such appointments. This was followed by formation of a search committee. Such was the path followed for the recruitments of Tony Reid, MD, PhD, Gregory Daniels, MD, PhD and Catriona Jamieson, MD, PhD, the promising new translational research scientists that have joined the Moores Cancer Center. Pilot projects are employed to actualize other parts of the plan for the Center; i.e., mentoring our more junior clinical scientists and developing translational research projects with clinical endpoints. These objectives come to life with two recently implemented pilot project competitions - the Mentored Translational Research Award program and the Collaborative Translational Research Award program, fully described below. The programs are announced annually to the Cancer Center membership at six month intervals, with robust competition and selection in NIH multi-tiered review fashion. Pilot project funding from the CCSG is also matched by other funds in the Cancer Center. Joint recruitment between the Center and the Department of Bioengineering, including the allocation of an FTE, is ongoing for an accomplished cancer bioengineering scientist. Through the use of campus start-up funding and 3 assigned FTEs, Nicholas Schork, PhD, a UCSD professor of psychiatry specializing in bioinformatics, was recruited in 2005 as a new investigator and leader of our bioinformatics program. No CCSG funds were required for his recruitment, although the CCSG may be allocated to the further growth of this key area. Developing technologies and shared resources is ongoing with new scientific directions, needs assessment through periodic member surveys, and leadership determination of optimal support services. Over this past project period we have invested in technologies targeted at improved analysis of genomics data. Future services have been given serious consideration by Cancer Center members and leaders alike, with proposed CCSG allocations for three developing facilities closely mirroring the programmatic priorities of the Center. These are described in detail below